PGHL Q1 FY27 Sales Up 7% to ₹356 Cr, PAT Jumps 45% to ₹96 Cr
Procter & Gamble Health Limited reported Q1 FY27 results with sales up 7% to ₹356 crores and PAT up 45% to ₹96 crores. Operational PAT increased 9% to ₹72 crores, excluding a one-time asset sale gain. MD Milind Thatte noted strong momentum driven by innovations and operational improvements.
The substantial increase in PAT, driven by both core business growth and a one-time gain, along with positive commentary from the MD, indicates a strong positive impact on the company's financial standing and investor confidence.
The company reported significant growth in both sales and profit, exceeding expectations and demonstrating strong operational performance.
Procter & Gamble Health Limited (PGHL) announced its first quarter results for the period ended June 30, 2026. The company reported a sales growth of 7% to ₹356 crores compared to the previous year, attributed to strong brand performance, effective retail execution, and positive consumer reception to new product innovations.
Profit After Tax (PAT) saw a significant increase of 45% to ₹96 crores. This surge was driven by sales growth, enhanced supply chain and go-to-market capabilities, and a one-time gain from the sale of an immovable asset. Excluding this one-time proceeds, the operational PAT grew by 9% to ₹72 crores.
Mr. Milind Thatte, Managing Director, P&G Health India, expressed satisfaction with the strong start to the financial year 2026-2027, highlighting sustained top-line and bottom-line growth. He credited this performance to consumer response to science-backed innovations, new communication initiatives, and improved operational capabilities. The company remains focused on delivering balanced growth and value creation through a strategy centered on a focused portfolio of quality brands, superiority in product and communication, constructive disruption, productivity, and an agile organization.
What to do with a filing like this
Procter & Gamble Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Health Limited. Read the original for the full detail.